Blog

– The webinar will take place on Wednesday, July 24, 2024 at 8:00 a.m. ET –

– Retinal specialists provide insights and practical experience with suprachoroidal drug delivery –

– Target profile for CLS-AX in the wet AMD environment and potential opportunities to expand the clearside pipeline –

ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS).^®), announced plans to host a virtual event for Key Opinion Leaders (KOL) on Wednesday, July 24, 2024 from 8:00 a.m. to 9:15 a.m. ET.

The event will highlight the broad applicability and real-world experience with suprachoroidal drug delivery, SCS as a differentiator in the field of retinal treatment with a focus on neovascular age-related macular degeneration (wet AMD), and ongoing SCS clinical programs, including potential future development opportunities for Clearside.

The event will include presentations from the following retina experts and will culminate with a live Q&A session with Clearside KOLs and senior management:

• David M. Brown, MD, Director of Research, Retina Consultants Houston

• Glenn C. Yiu, MD, Ph.D., Professor of Ophthalmology, University of California, Davis

• Victor Chong, MD, MBA, Chief Physician, Clearside Biomedical

The live and archived webcast will be available on the Clearside website in the Investors: Events and Presentations section.

Biographies of retina specialists

David M. Brown, MD., Director of Research at Retina Consultants Houston, is a medical and surgical retina specialist and clinical trials specialist. He has pioneered research in the areas of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. He is director of the Greater Houston Retina Research Center, clinical professor of ophthalmology at Baylor College of Medicine, associate director of research at the Blanton Eye Institute at Houston Methodist Hospital, and serves as a consulting retina specialist for NASA. Dr. Brown received his medical degree from Baylor College of Medicine and completed training in ophthalmology and retina at the University of Iowa.

Glenn C. Yiu, Dr., Ph.D. is a professor of ophthalmology at the University of California, Davis, where he works as a clinician-scientist and provides patient care as a board-certified vitreoretinal surgeon. He earned his dual MD-PhD degrees from Harvard Medical School, completed a residency at the Massachusetts Eye & Ear Infirmary, and a vitreoretinal fellowship at Duke University. He joined UC Davis in 2014, where he leads a translational research program studying age-related macular degeneration (AMD) and other retinal diseases, with a focus on ocular imaging technologies, genome editing and delivery, and animal models of retinal disease. He reported the first use of CRISPR-based genome editing as a treatment strategy for wet AMD, developed the use of microneedles for suprachoroidal gene delivery, and pioneered important studies of AMD and other retinal disease models in nonhuman primates. He is also the associate director of Davis-Based Medical Student Research and director of teleophthalmology at UC Davis, where he pioneered a teleretinal screening program to expand eye screening among diabetes patients in California.

The story goes on

Victor Chong, MD, MBAChief Medical Officer of Clearside Biomedical, is a board-certified retinal specialist. Previously, Dr. Chong was VP, Global Head of Retina DAS at Johnson & Johnson Innovative Medicine, Global Head of Medicine, Retinal Health at Boehringer Ingelheim and Division Head and Consultant Ophthalmic Surgeon at Oxford Eye Hospital, part of Oxford University Hospitals. Dr. Chong graduated from the University of Glasgow Medical School (MBChB) with the Neil Arnott Prize, completed his ophthalmology training at Moorfields Eye Hospital and completed a retinal fellowship at the Institute of Ophthalmology and Moorfields Eye Hospital in London. He holds an MD by Research in Ophthalmology from King’s College, an MBA from the Quantic School of Business and Technology and an MPhil in Cell Biology and Pathology from University College London.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS).^®). Clearside’s SCS injection platform, which utilizes the company’s patented SCS microinjector^®enables an office-based, repeatable, non-surgical procedure to deliver a variety of therapies in a targeted and compartmentalized manner to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for delivery via its SCS microinjector. The Company’s lead program, CLS-AX (axitinib suspension for injection) for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical development. Clearside has developed and received approval for its first product, XIPERE® (triamcinolone acetonide suspension for injection) for suprachoroidal use and is available in the U.S. through a commercial partner. Clearside also strategically collaborates with companies leveraging other ophthalmic therapeutic innovations using its SCS injection platform. For more information, visit clearsidebio.com. Follow us on LinkedIn and X.

Cautionary note regarding forward-looking statements

Any statements other than statements of historical fact included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as “believe,” “expect,” “could,” “plan,” “potential,” “will” and similar expressions and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the potential benefits of CLS-AX, Clearside’s suprachoroidal delivery technology and Clearside’s SCS microinjector.^®and potential future clinical development opportunities and pipeline expansions for Clearside. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in these statements. Risks and uncertainties that could cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s dependence on third parties over which it may not always have full control, and other risks and uncertainties described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC) on March 12, 2024, and Clearside’s other periodic reports filed with the SEC. All forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this press release, and Clearside undertakes no obligation and does not intend to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact for investors and media:

Jenny Kobin
Daniela
[email protected]
(678) 430-8206

Source: Clearside Biomedical, Inc.